Validation of a genetic-engineering technology for the production of industrial enzymes
| Reference number | |
| Coordinator | CLONEOPT AB |
| Funding from Vinnova | SEK 483 373 |
| Project duration | September 2018 - December 2019 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups phase 2 spring 2018 |
Important results from the project
CloneOpt AB is a Swedish bioengineering company that is commercializing a technology for producing proteins in bacterial cell factories. Funding obtained through the Vinnova Innovative startups fas 2 program was used by CloneOpt to try and enter the market for industrial enzymes.
Expected long term effects
CloneOpt carried out market research, generated promising preliminary data and developed expertise in the production and testing of industrial enzymes. They are now leveraging this expertise to engage other companies in proof of principle projects.
Approach and implementation
During the course of the project, CloneOpt learnt that companies already engaged in product development do not want to take on new technologies. They are however, interested to know about new technologies when starting up new projects. This information will help us refine potential customers.